

## **What medical societies have recognized icosapent ethyl (VASCEPA®/VAZKEPA) in their medical treatment guidelines or scientific statements?**

A growing number of medical societies are recommending the usage of icosapent ethyl (VASCEPA/VAZKEPA) in appropriate patients. In addition to recommending the use of icosapent ethyl, many of these guidelines emphasize that the positive clinical results of the REDUCE-IT® cardiovascular outcomes study should not be generalized to any product other than icosapent ethyl (i.e., the clinical results are unique to VASCEPA).

Medical societies that have updated their guidelines and/or issued scientific statements include:

### North America

- American Diabetes Association (ADA)
- American Heart Association (AHA)
- American Stroke Association (ASA)
- National Lipid Association (NLA)
- American Association of Clinical Endocrinologists (AACE)
- American College of Endocrinology (ACE)
- Thrombosis Canada
- Endocrine Society (ENDO)
- Canadian Cardiovascular Society (CCS)
- Canadian Stroke Best Practice Recommendations Advisory Committee, in collaboration with the Canadian Stroke Consortium
- American College of Cardiology (ACC)
- Diabetes CardioRenal Metabolic Diseases (DCRM) Task Force
- Heart Failure Society of America (HFSA)

### Europe

- European Society of Cardiology (ESC)
- European Atherosclerosis Society (EAS)
- Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy (SFSN PTK)
- Spanish Society of Diabetes (SED)
- Polish Lipid Association (PoLA)
- College of Family Physicians in Poland (CFPiP)
- Polish Cardiac Society (PCS)
- Polish Society of Laboratory Diagnostics (PSLD)
- Polish Society of Diabetology (PSD)
- Polish Society of Hypertension (PSH)

### South America

- Brazilian Society of Cardiology (SBC)
- Colombian Association of Endocrinology, Diabetes and Metabolism, Colombian Society of

## Cardiology and Cardiovascular Surgery

### Asia/Africa

- Japan Circulation Society (JCS)
- Chinese Society of Cardiology (CSC)
- Chinese Journal of Internal Medicine (a journal of the Chinese Medical Association [CMA])
- The Egyptian Heart Journal (the official journal of the Egyptian Society of Cardiology)
- Chinese Association of Cardiovascular Surgeons (CACS)/Chinese Society of Thoracic and Cardiovascular Surgery (CSTCVS)
- Japan Stroke Society (JSS)

### Middle East

- Saudi National Diabetes Center (SNDC)

Below are more details regarding these guidelines and scientific statements (listed in chronological order):

- The American Diabetes Association (ADA) updated their *Standards of Medical Care in Diabetes* in March of 2019 to recommend that icosapent ethyl be considered for patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) or other cardiac risk factors on a statin with controlled low-density lipoprotein cholesterol (LDL-C), but with elevated triglyceride (TG) levels (135–499 mg/dL) to reduce cardiovascular (CV) risk.<sup>1</sup>
  - The findings were made with a level “A” grade of scientific evidence, which under ADA standards, reflects that REDUCE-IT was considered to be a large well-designed clinical trial. Generally, according to ADA, A-level recommendations have the best chance of improving outcomes when applied to the population to which they are appropriate.<sup>1</sup>
  - The ADA is a United States–based nonprofit that seeks to prevent and cure diabetes and to improve the lives of all people affected by diabetes.<sup>2</sup>
- In May 2019, the Japan Circulation Society (JCS) referenced REDUCE-IT and eicosapentaenoic acid (EPA) in their publication of updated guidelines.<sup>3</sup>
- The American Heart Association (AHA) issued a Scientific Advisory in August of 2019 recognizing that elevated TG levels may be a causal factor for CV disease (CVD); that dietary supplements are not recommended, nor FDA approved, to treat medical conditions; and that positive outcomes results were demonstrated in REDUCE-IT.<sup>4</sup>
  - The AHA is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke.<sup>4</sup>

- The European Society of Cardiology (ESC) updated their patient treatment guidelines on August 31, 2019 to include icosapent ethyl in combination with statins to address high-risk CV patients with elevated TG levels (135–499 mg/dL). They updated their guidelines jointly with the European Atherosclerosis Society (EAS). The classification is a Level B recommendation, which reflects a relatively high weight of scientific evidence under ESC and EAS standards.<sup>5</sup>
  - ESC is a not-for-profit medical society led by expert volunteers. They unite Member National Cardiac Societies, cardiovascular ESC subspecialty communities, Affiliated Cardiac Societies, distinguished Fellows of the ESC, and individual members from around the world.<sup>5</sup>
  - The EAS joined ESC to jointly issue the above-described patient treatment guidelines.
  - EAS was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease.” For more than 50 years, the society’s expertise has been used to teach clinicians how to manage lipid disorders and prevent atherosclerosis.<sup>6</sup>
- The National Lipid Association (NLA) issued a position statement on September 13, 2019 recommending icosapent ethyl for ASCVD risk reduction in high- and very-high-risk patients, 45 years of age or older with clinical ASCVD, or 50 years of age or older with type 2 diabetes requiring medication and with ≥1 additional risk factor, and fasting TG levels of 135–499 mg/dL on maximally tolerated statin, with or without ezetimibe. The NLA recommendation was issued as a Class I, Level B-R (STRONG) recommendation, its highest designation, for icosapent ethyl.<sup>7</sup>
  - The NLA is a leading professional society dedicated to enhancing the practice of lipid management in clinical medicine.<sup>7</sup> The NLA’s Board of Directors comprises leading experts who specialize in clinical lipidology.
- In November 2019, The Brazilian Society of Cardiology (SBC) released an *Updated Cardiovascular Prevention Guideline*. SBC has 12 scientific departments and 10 study groups, as well as an organization in 26 regional societies throughout Brazil.<sup>8</sup>
- SBC provided the following update regarding icosapent ethyl:
  - Supplementation with an E-EPA (ethyl eicosapentaenoic acid) formulation (4 g/day) can be recommended for high-risk patients with elevated TG levels using statins, as it seems to reduce the risk for ischemic events, including CV death (Grade I, Level B evidence).

- Omega-3 supplementation (EPA) at a dose of 4 g per day can be administered to patients in secondary prevention who use statins and have TG levels between 150 and 499 mg/dL (Grade II, Level B evidence).
- Data from these studies suggest that high doses of EPA (4 g) can be used in patients with prior CVD and who remain with elevated TG levels, despite taking statins to prevent CVD. However, there is no evidence for the use of lower doses and other formulations of omega-3 for CV prevention, both primary and secondary.
- In January 2020, a consensus statement by the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) on the comprehensive management of type 2 diabetes was released.<sup>9,10</sup> The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension, and glucose-management strategies. It is the most up-to-date and progressive management algorithm; it includes strategies based on all the newest diabetes and related metabolic CV outcomes trials and incorporates the latest FDA-approved indications.<sup>9</sup>
  - Strategies included in the 2020 AACE diabetes algorithm go beyond just managing and controlling CV risk factors to preventing subsequent CV events, including morbidity and mortality in patients with established ASCVD and those at high risk for CVD.<sup>9</sup>
  - The specific update regarding icosapent ethyl in the new guidance includes the following:
    - Management of patients with established or at high risk for CVD who have TG levels between 135 and 499 mg/dL with EPA with proven benefits to prevent the next event<sup>9</sup>
- In February 2020, the *Thrombosis Canada Clinical Guide on Stroke–Secondary Prevention* was updated. This update mentions icosapent ethyl as a therapeutic approach to reduce the risk of recurrent vascular events in patients who have already suffered a stroke or transient ischemic attack (TIA).<sup>11</sup>
  - The Thrombosis Canada clinical guides have been developed to assist clinicians with point-of-care decision making. They are not intended to be taken as guidelines. The Thrombosis Canada Clinical Guides are:
    - Developed voluntarily by Thrombosis Canada members, who are

internationally recognized as experts

- Peer reviewed by the Thrombosis Canada Clinical Guide Committee
  - Reviewed for applicability to primary care by members of the College of Family Physicians of Canada
  - Reflect recommendations of evidence-based clinical practice guidelines
  - Not supported financially by any external funders
- In February 2020, the Colombian Association of Endocrinology, Diabetes and Metabolism and the Colombian Society of Cardiology and Cardiovascular Surgery published the recommendations of the expert panel on the diagnostic pathophysiology and treatment of dyslipidemias in the adult population<sup>12</sup>:
    - Issued post FDA approval in US and prior to application in Columbia
    - Referenced the REDUCE-IT results and the CV risk-lowering effects of icosapent ethyl in joint dyslipidemia recommendations
    - Recommends pharmacologic forms of omega-3 fatty acids (non-supplements) and in doses of 4 g/day (as described in the REDUCE-IT study, where icosapent ethyl was administered as 2 g every 12 hours)
  - On April 13, 2020, The AHA issued the *Scientific Statement on the Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus*.<sup>13</sup>
    - Within this scientific statement, the AHA identifies icosapent ethyl as a first-line therapy consideration for further CV risk reduction when TG levels remain elevated (>135 mg/dL) despite maximally tolerated statin based on the results of REDUCE-IT.
  - In August 2020, the ESC updated guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.<sup>14</sup>
    - These guidelines reference the REDUCE-IT results in the guidelines for the management of non-ST elevation-acute coronary syndrome
    - Highlights use of very high doses of icosapent ethyl (2 g twice daily)
    - Refers to the icosapent ethyl IIa recommendation in 2019 ESC/EAS guidelines for the management of dyslipidemias
  - In October 2020, The Endocrine Society (ENDO) published their *Full Guideline: Lipid*

*Management in Patients with Endocrine Disorders.*<sup>15</sup>

- Within this guideline, based upon the results of REDUCE-IT, ENDO recommends that icosapent ethyl should be considered first-line therapy in patients on statin therapy with TG levels >150 mg/dL and with either ASCVD or diabetes plus 2 additional risk factors.
  - The guideline also conveys that CVD benefit seen in REDUCE-IT does not apply to other omega-3 fatty acids, particularly those with a mix of EPA and docosahexaenoic acid (DHA).
- In December 2020, the Chinese Society of Cardiology (CSC) published their *Guidelines for Primary Prevention of Cardiovascular Diseases in China*.<sup>16</sup>
  - The guidelines reference the use of icosapent ethyl (as studied in REDUCE-IT).
  - If TG level is >2.3 mmol/L in people at high risk of ASCVD after receiving moderate-dose statin therapy, consider giving high-dose EPA ethyl ester (icosapent ethyl) (2 g, twice daily) to further reduce the risk of ASCVD (Category IIa, Evidence Level B)
- In February 2021, the *Egyptian Heart Journal* published a practical guidance in lipid management. In this guidance, icosapent ethyl was listed as a consideration in patients with high TG levels (>200 mg/dL). The recommendation states to exclude and treat secondary causes of hypertriglyceridemia (TG levels >200 mg/dL). Patients with hypertriglyceridemia and at high risk must receive a statin as a first-line treatment to reduce CVD risk. In high-risk (or above) patients with TG levels between 135 and 499 mg/dL despite statin treatment, omega-3 polyunsaturated fatty acids (icosapent ethyl 2 × 2 g/day) should be considered in combination with a statin.<sup>17</sup>
- In March 2021, the Canadian Cardiovascular Society (CCS) published their *Guidelines for Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult*.<sup>18</sup> In this guidance, icosapent ethyl was recommend for use to lower the risk of CV events in patients with ASCVD, or with diabetes and ≥1 CVD risk factors, who have an elevated fasting TG level of 1.5–5.6 mmol/L despite treatment with maximally tolerated statin therapy (Strong Recommendation; High-Quality Evidence). In addition, the guidelines do not recommend the use of over-the-counter omega-3 polyunsaturated fatty acids supplements (marketed as natural health products in Canada) to reduce CVD risk (Strong Recommendation; High-Quality Evidence).<sup>18</sup>

- In April 2021, the Task Force for Coronary Heart Disease of the Chinese Association of Cardiovascular Surgeons (CACS) and the Task Force for Coronary Heart Disease of the Chinese Society of Thoracic and Cardiovascular Surgery (CSTCVS) jointly developed a consensus statement on secondary prevention after coronary artery bypass surgery.<sup>19</sup> The consensus was developed with input from domestic experts across multiple disciplines, including cardiac surgery, cardiology, endocrinology, neurology, nephrology, gastroenterology, rehabilitation, and others, as well as recommendations from a number of key organizations including the Chinese Medical Association, Chinese Medical Doctor Association, and mainstream European and American associations.<sup>19</sup>
  - The consensus states that for patients with concomitant hypertriglyceridemia following coronary artery bypass surgery, supplementation with high-purity EPA, instead of omega-3 polyunsaturated fatty acids blended with DHA, can be considered for secondary prevention to further reduce CV events. The authors indicate this is similar to an evidence-based Class IIb recommendation, where the benefits balance or outweigh the risks.<sup>19</sup>
- In May 2021, the China National Health Commission Capacity Building and Continuing Education Center published the *Expert Consensus on Diagnosis and Treatment of Diabetic Patients With Cardiovascular Disease* in the *Chinese Journal of Internal Medicine*<sup>20</sup> (one of the journals of the Chinese Medical Association), which references icosapent ethyl:
  - On the basis of strict lifestyle intervention and statin therapy, patients at high risk/extremely high risk for CVD tend to use high-dose ethyl eicosapentaenoate (also known as icosapent ethyl) (2 g, twice daily) to further reduce the risk for CVD if TG levels are >2.3 mmol/L.
- In May 2021, the AHA/American Stroke Association (ASA) published the *2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack*.<sup>21</sup> This guideline was reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and Congress of Neurological Surgeons; endorsed by the Society of Vascular and Interventional Neurology; and the American Academy of Neurology affirmed the value of this statement as an educational tool for neurologists.
  - This stroke guideline from the AHA/ASA contains the following recommendations:
    - In patients with ischemic stroke or TIA, with fasting TG levels 135 to 499 mg/dL and

LDL-C of 41 to 100 mg/dL, on moderate- or high-intensity statin therapy, with HbA1c <10%, and with no history of pancreatitis, atrial fibrillation, or severe heart failure, treatment with icosapent ethyl 2 g twice a day is reasonable to reduce risk of recurrent stroke.

- This guideline also recognized the potential mechanism of CV risk reduction with icosapent ethyl as well as differences between icosapent ethyl/EPA as compared to DHA, another omega-3 fatty acid, with the following language:
  - Because TG levels were similar, higher EPA levels may account for the results seen in REDUCE-IT. In addition, the differing effects of EPA and DHA on membrane stabilization may contribute to the lack of effect with EPA/DHA compared with EPA alone or icosapent ethyl.
- In June 2021, the Canadian Stroke Best Practice Recommendations Advisory Committee, in collaboration with the Canadian Stroke Consortium, published the *Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020*, which was published in the *Canadian Journal of Neurological Sciences*.<sup>22</sup>
  - This stroke best practices paper contains the following new recommendation regarding icosapent ethyl:
    - Add-on therapies for hypertriglyceridemia (NEW 2020)
      - For ischemic stroke patients with established ASCVD or diabetes plus additional vascular risk factors, who have elevated serum TG levels ( $\geq 1.5$  mmol/L) despite statin therapy, icosapent ethyl 2 g bid may be considered to decrease the risk of vascular events (Level of Evidence B).
- In June 2021, the Hypertension Study Group of the Chinese Society of Cardiology, Chinese Medical Association, published a consensus statement on the management of blood pressure and dyslipidemia in Chinese patients with hypertension.<sup>23</sup> The consensus statement emphasizes the importance of blood lipid management in hypertensive patients for the prevention of ASCVD, and notes that high-dose icosapent ethyl (2 g, twice per day) can reduce TG levels and the incidence of CV events “to some extent.”
- In July 2021, the American College of Cardiology (ACC) published the *2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent*



*Hypertriglyceridemia*.<sup>24</sup> This consensus document was reviewed and endorsed by the National Lipid Association (NLA) and published in the *Journal of the American College of Cardiology* (<https://www.jacc.org/doi/pdf/10.1016/j.jacc.2021.06.011>).

- ACC developed this consensus document to address current gaps in care for high-risk patients with mild to moderate hypertriglyceridemia (fasting TG levels  $\geq 150$  mg or non-fasting TG levels  $\geq 175$  mg/dL and  $< 500$  mg/dL) and severe hypertriglyceridemia (fasting TG levels  $\geq 500$  mg/dL and especially TG levels  $\geq 1000$  mg/dL). The goal was to provide practical guidance for clinicians and patients in situations not covered by the 2018 AHA/ACC/multi-society cholesterol guideline.
  - The document reports that non-prescription fish oil products are classified as dietary supplements and are not interchangeable with prescription omega-3 products.
  - This document also reports that the only TG risk-based non-statin therapy approved for reduction in ASCVD risk by the US FDA is icosapent ethyl.
  - In adults with clinical ASCVD and fasting TG levels  $\geq 150$  or non-fasting TG levels  $\geq 175$  mg/dL and TG levels  $< 500$  mg/dL, and on statins with LDL-C  $< 70$  or 70–100 mg/dL, icosapent ethyl may be considered.
  - In adults aged  $\geq 50$  years with diabetes mellitus and additional CVD risk factor(s) and fasting TG levels  $\geq 150$  or non-fasting TG levels  $\geq 175$  mg/dL and TG levels  $< 500$  mg/dL, and on maximally tolerated statin therapy, icosapent ethyl may be considered.
- In August 2021, the ESC released their *2021 Guidelines on Cardiovascular Disease Prevention in Clinical Practice*.<sup>25</sup> This guideline was developed by the Task Force for Cardiovascular Disease Prevention in Clinical Practice with representatives of the ESC and 12 medical societies and the special contribution of the European Association of Preventive Cardiology (EAPC).
  - Icosapent ethyl may be considered for patients with diabetes mellitus and established ASCVD and/or severe target organ damage or with established ASCVD
  - In high-risk (or above) patients with TG levels  $> 1.5$  mmol/L (135 mg/dL) despite statin treatment and lifestyle measures, omega-3 polyunsaturated fatty acids (IPE 2 x 2 g/day) may be considered in combination with a statin (Class IIb). The classification is a Class IIb

recommendation, which reflects a relatively high weight of scientific evidence under ESC and EAS standards.

- In August 2021, the Saudi National Diabetes Center (SNDC) issued the *Saudi Diabetes Clinical Practice Guidelines*<sup>26</sup> (SDCPG) to give healthcare providers practical guidance in caring for patients with diabetes. This first edition of the guidelines was developed by adult and pediatric endocrinologists from different healthcare sectors in the Kingdom of Saudi Arabia, and guided by state-of-the-art literature and recommendations from other major organizations including the ADA, AACE, National Institute for Health and Care Excellence (NICE), and the International Diabetes Federation. The authors note that a grading system for the considered evidence was not employed for this first edition, but will be implemented in future updates.
  - In its recommendations for lipid management in patients with diabetes and for adults with adults with moderate hypertriglyceridemia (fasting or nonfasting TG levels 175–499 mg/dL), the SDCPG mentions that icosapent ethyl was shown to reduce CV events, including deaths, in patients with elevated TG levels. However, the guidelines also note that icosapent ethyl is not available in the Kingdom of Saudi Arabia.<sup>26</sup>
- In November 2021, the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy (SFSN PTK) published a consensus statement on the management of dyslipidemia. This is the fourth edition of the consensus statement from SFSN PTK in an effort to keep abreast of the current treatment landscape of dyslipidemia in Poland.<sup>27</sup>
  - In its statement, SFSN PTK recommends EPA 4 g daily in combination with statins for patients with TG levels 135–499 mg/dL in the high- and very-high-risk categories.
  - The consensus statement mentions that in REDUCE-IT, icosapent ethyl 2 g twice daily in combination with a statin significantly reduced the risk of CV events and lowered TG levels.
  - SFSN PTK acknowledges that icosapent ethyl is not approved for use in Poland, and data from REDUCE-IT cannot be extrapolated to other doses and formulation of omega-3s.
- In November 2021, 6 medical societies, including the Polish Lipid Association (PoLA), the College of Family Physicians in Poland (CFPiP), the Polish Cardiac Society (PCS), the Polish Society of Laboratory Diagnostics (PSLD), the Polish Society of Diabetology (PSD), and the Polish Society of Hypertension (PSH) released guidelines on the diagnosis and therapy of lipid disorders in Poland, with the following key recommendations regarding IPE<sup>28</sup>:

- In at least high-risk patients with TG levels  $\geq 1.7$  mmol/L ( $\geq 150$  mg/dL) despite statin treatment, IPE (2 x 2 g/day) in combination with a statin should be considered if IPE is available.
  - Recommendation notes the increased risk of atrial fibrillation with use of IPE.
- IPE is not yet available in Poland; in at least high-risk patients with TG levels  $\geq 2.3$  mmol/L ( $\geq 200$  mg/dL) despite statin therapy, omega-3 acids (PUFA in a dose of 2–4 g/day) in combination with a statin may be considered.
- For patients with type 2 diabetes without ASCVD, fenofibrate should be considered; if TG goal is not reached, high-dose omega 3-acids/IPE should be considered.
- In December 2021, the Diabetes CardioRenal Metabolic Diseases (DCRM) Task Force published practice recommendations for the management of DCRM.<sup>29</sup>
  - IPE is recommended for primary prevention of myocardial infarction, coronary artery disease, or stroke in patients with diabetes and for secondary prevention of these events in those with and without diabetes.
  - Based on evidence from REDUCE-IT, adding IPE to statin therapy further reduces the risk of ASCVD events in patients with TG levels 135–500 mg/dL (1.5–5.7 mmol/L) who have ASCVD or diabetes plus 2 major ASCVD risk factors.
- In 2019, a panel of regional experts in plasma lipid disorders met to update the 2016 *Consensus Clinical Recommendations for the Management of Plasma Lipid Disorders in the Middle East*, using the latest evidence and recommendations from international guidelines.<sup>30</sup> The update was published in December 2021 and:
  - References the REDUCE-IT results and the CVD risk–lowering effects of IPE and noted that CVD reduction may be related to action of EPA independent of TG lowering
  - States that elevated TG levels are associated with increased ASCVD risk and patients with elevated TG levels ( $\geq 150$  mg/dL) should be considered for more aggressive LDL-C lowering as well as lowering of TGs
  - Recommends that if TG, non-HDL-C, or ApoB goals are not met with statins and lifestyle modifications, further options include ezetimibe, PCSK9 inhibitors, or IPE
- In January 2022, the American Heart Association issued a scientific statement on the comprehensive management of CV risk factors for adults with type 2 diabetes.<sup>31</sup>
  - In patients with diabetes and ASCVD or patients with diabetes at high risk for ASCVD with serum TG levels of 135–500 mg/dL despite maximally tolerated statin therapy, and

addressing contributory factors including lifestyle modification, prescription IPE at a dose of 4 g/d should be considered given the 30% additional CV risk reduction in the REDUCE-IT trial.

- For primary prevention in type 2 diabetes, a moderate-intensity statin should be considered based on age, absolute ASCVD risk, or the presence of risk-enhancing factors. Non-statin therapies including ezetimibe, PCSK9 inhibitors, IPE, bile acid resins, and fibrates should be considered after thorough evaluation of risk, LDL-C level after optimal statin therapy, and presence of hypertriglyceridemia.
- In January 2022, the ADA updated their *Standards of Medical Care in Diabetes*. Their recommendation regarding use of IPE did not change since the 2019 update.<sup>32</sup>
  - In patients with ASCVD or other CV risk factors on a statin with controlled LDL-C but elevated TG levels (135–499 mg/dL), the addition of IPE can be considered to reduce CV risk.
- In January 2022, the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes published an update on recommendations regarding diabetes and CV risk, with the following key recommendations<sup>33</sup>:
  - In patients with ASCVD or other CV risk factors with LDL-C within targets but high TG levels (135–499 mg/dL), the addition of IPE should be considered to reduce CV risk (strong recommendation, moderate evidence); guidelines cite results from REDUCE-IT as a basis for this recommendation.
- In April 2022, the ACC and AHA partnered with the Heart Failure Society of America (HFSA) to develop guidelines for the management of heart failure. These guidelines replace the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.” The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. The following are key recommendations related to use of omega-3 fatty acids<sup>34</sup>:
  - In patients with HF class II to IV symptoms, omega-3 polyunsaturated fatty acid supplementation may be reasonable to use as adjunctive therapy to reduce mortality and CV hospitalizations.
    - This recommendation is based on evidence from several studies, including

REDUCE-IT, which randomized patients with established CVD or diabetes with risk factors to 2 g of IPE twice daily or placebo and showed a reduced risk for the composite of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina.

- The guidelines mention that there is a dose-related risk of atrial fibrillation with use of omega-3 fatty acid.
- In April 2022, the Japan Stroke Society released extracted recommendation statements from the revised Japan Stroke Society Guideline for the Treatment of Stroke that was published in July 2021.<sup>35</sup> This guideline is developed every 6 years, with updates every 2 years in the intervening periods. The guideline has been developed in conjunction with the Japan Neurosurgical Society, the Japanese Society of Neurology, the Japanese Association of Rehabilitation Medicine, the Japanese Society of Neurological Therapeutics, the Japanese Society on Surgery for Cerebral Stroke, and the Japanese Society for Neuroendovascular Therapy. The guideline covers primary prevention, general acute management of stroke, ischemic stroke and transient ischemic attack, intracerebral hemorrhage, subarachnoid hemorrhage, asymptomatic cerebrovascular disease, other cerebrovascular disease, and rehabilitation. The guideline includes the following key recommendation regarding use of IPE:
  - In patients with ischemic stroke under lipid control with statin, coadministration of ethyl icosapentate product for prevention of stroke recurrence is reasonable (Moderate Recommendation, Low Evidence).
- In May 2022, the CCS published guidelines on best practices to manage peripheral arterial disease, with the following key recommendations regarding IPE<sup>36</sup>:
  - In patients with peripheral arterial disease, who, despite a maximally tolerated dose of statin therapy have a TG level of 1.5–5.6 mmol/L, should be considered for use of IPE for the reduction of CV death, nonfatal MI, and nonfatal stroke concordant with the recommendations in the 2021 CCS guidelines for the management of dyslipidemia (Strong Recommendation; Moderate-Quality Evidence).

- Evidence for reduction of major adverse limb events or peripheral arterial disease patient-relevant outcomes is not yet available for IPE.
- For the reduction of major adverse CV events, patient-physician decisions that accommodate patient preferences, priorities, and access issues will determine when it is appropriate to consider IPE for patients with peripheral arterial disease.
- In June 2022, the NLA released a statement on statin intolerance titled A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient.<sup>37</sup> The statement acknowledged that statin intolerance can compromise management of ASCVD and proposed the use of non-statin pharmacologic therapies, including IPE, as an option for patients with statin intolerance. The statement elaborated that non-statin therapies can be used as an adjunct or alternative to statin therapy to achieve therapeutic objectives. It cited data from REDUCE-IT as evidence of the efficacy of IPE in lowering atherogenic lipoproteins and CV events, adding that the effect of IPE on CV events is likely attributed to mechanisms that go beyond the lowering of lipid parameters.

VASCEPA and VAZKEPA are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

## References

1. 10. Cardiovascular disease and risk management: standards of medical care in diabetes — 2019. *Diabetes Care*. 2019;42(Suppl 1):S103-S123.
2. Connected for life. Strategic architecture. 2020. Available at: <http://main.diabetes.org/dorg/bod/2019-2020/ADA-Strategic-Architecture.pdf>. Accessed: November 29, 2021.
3. Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. *Circ J*. 2019;83(5):1085-1196.
4. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. *Circulation*. 2019;140(12):e673-e691.
5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J*. 2020;41(1):111-188.
6. About EAS. 2021. Available at: [https://www.eas-society.org/page/about\\_eas](https://www.eas-society.org/page/about_eas). Accessed: November 29, 2021.
7. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. *J Clin Lipidol*. 2019;13(6):860-872.
8. Precoma D, De Oliveira JM, Simao A, et al. Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology—2019. *Arq Bras Cardiol*. 2019;113(4):787-891.
9. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. *Endocr Pract*. 2020;26(1):107-139.
10. New updates to the AACE diabetes algorithm. 2020. Available at: <https://pro.aace.com/recent-news-and-updates/new-updates-aace-diabetes-algorithm>. Accessed: November 29, 2021.
11. Stroke: Secondary Prevention. 2020. Available at: [https://thrombosiscanada.ca/wp-content/uploads/2020/04/Stroke-Secondary-Prevention\\_26Feb2020-1.pdf](https://thrombosiscanada.ca/wp-content/uploads/2020/04/Stroke-Secondary-Prevention_26Feb2020-1.pdf). Accessed: May 8, 2020.
12. Vargas-Uricoechea H, Ruiz AJ, Gómez EA, et al. [Recommendations of the expert panel on pathophysiology, diagnosis and treatment of dyslipidemias in the adult population. Colombian Association of Endocrinology, Diabetes and Metabolism and Colombian Society of Cardiology and Cardiovascular Surgery]. *Revista Colombiana de Endocrinología Diabetes & Metabolismo*. 2020;7(Suppl 1):1-38.
13. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. *Circulation*. 2020;141(19):e779–e806.
14. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2021;42(14):1289-1367.
15. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2020;105(12).
16. Chinese guideline on the primary prevention of cardiovascular diseases. *Chinese J Cardiol*. 2020;48(12):1000-1038.
17. Taha H, Badran HM, Kandil H, et al. Egyptian practical guidance in lipid management 2020. *Egypt Heart J*. 2021;73(1):17.
18. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for

- the management of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol*. 2021;37(8):1129-1150.
19. Chinese expert consensus on secondary prevention after coronary artery bypass surgery (2020). *Chin J Thorac Cardiovasc Surg*. 2021;37(4):193-203.
  20. Sun YH, Chen K, Chen X, et al. Expert consensus on the management of diabetic patients with cardiovascular diseases. *Chinese J Intern Med*. 2021;60(5):421-437.
  21. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021;52(7):e364-e467.
  22. Gladstone DJ, Lindsay MP, Douketis J, et al. Canadian Stroke best practice recommendations: secondary prevention of stroke update 2020. *Can J Neurol Sci*. 2022;49(3):315-337.
  23. Expert consensus on the comprehensive management of blood pressure and dyslipidemia in Chinese hypertensive patients. *Chin J Cardiol*. 2021;49(6):554-563.
  24. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78(9):960-993.
  25. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-3337.
  26. Saudi Diabetes Clinical Practice Guidelines (SDCPG). 2021. Available at: <https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Saudi-Diabetes-Clinical-Practice-Guidelines.pdf>. Accessed: September 24, 2021.
  27. Szymański FM, Mickiewicz A, Dzida G, et al. Management of dyslipidemia in Poland. Interdisciplinary expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy—the fourth declaration of Sopot. *Cardiol J*. 2021.
  28. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPIP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. *Arch Med Sci*. 2021;17(6):1447-1547.
  29. Handelsman Y, Anderson JE, Bakris GL, et al. DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications*. 2022;36(2):108101.
  30. Alsayed N, Almahmeed W, Alnouri F, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. *Atherosclerosis*. 2021;343:28-50.
  31. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. *Circulation*. 2022;145(9):e722-e759.
  32. Draznin B, Aroda VR, Bakris G, et al. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(Supplement\_1):S144-S174.
  33. Arrieta F, Pedro-Botet J, Iglesias P, et al. Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). *Clin Invest Arterioscler*. 2022;34(1):36-55.
  34. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895-e1032.
  35. Miyamoto S, Ogasawara K, Kuroda S, et al. Japan Stroke Society guideline 2021 for the treatment of stroke. *International journal of stroke : official journal of the International Stroke Society*. 2022;Apr 20 Online Ahead of Print.
  36. Abramson BL, Al-Omran M, Anand SS, et al. Canadian Cardiovascular Society 2022 guidelines for



- peripheral arterial disease. *Can J Cardiol.* 2022;38(5):560-587.
37. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient. *J Clin Lipidol.* 2022; Pre-proof.